A Virginia Republican congressman has come out in measured support of the DEA's proposed move to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act - and his reasoning centers less on market access than on what he sees as a product safety emergency hiding in plain sight. Rep. Morgan Griffith of Southwest Virginia told local broadcaster WJHL that rescheduling could help clean up an industry where unregulated, often foreign-sourced hemp-derived products have proliferated in unlicensed retail channels, frequently outside the reach of any state cannabis compliance framework. A federal administrative hearing on how the rescheduling would be implemented is scheduled for June 29.
The Product Safety Problem Griffith Is Describing
What Griffith is pointing to isn't abstract. The explosion of hemp-derived cannabinoid products - delta-8 THC, delta-10, HHC, and related compounds - has created a category that largely bypasses the testing, labeling, and potency verification requirements that licensed dispensaries must follow. These products appear in convenience stores, gas stations, and smoke shops. No certificate of analysis required at point of sale. No seed-to-sale tracking. No compliant packaging mandate enforced at the retail level. And, as Griffith notes, limited visibility into what's actually in them - particularly for products manufactured overseas and imported with minimal regulatory scrutiny.
Licensed cannabis operators know this terrain well. They operate under state-level compliance regimes that require third-party lab testing for potency and contaminants, child-resistant packaging, and strict age-gating at POS. The irony isn't subtle: a licensed dispensary selling a 10mg THC edible must document the product's chain of custody from cultivation through sale, while a hemp-derived product with potentially higher or unverified cannabinoid content sits next to the energy drinks at a truck stop.
What Rescheduling Would - and Wouldn't - Fix
Here's where it gets complicated. Moving marijuana to Schedule III would not, by itself, federalize cannabis retail or impose FDA product standards on the market overnight. Rescheduling would primarily affect FDA-approved drug products containing cannabis compounds - think pharmaceutical preparations that have cleared clinical trials - and would alter how existing federal law treats research, banking, and the tax treatment of plant-touching businesses under 280E. That last point matters enormously to licensed operators. Section 280E of the Internal Revenue Code currently prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, creating effective tax rates that can gut dispensary margins. Schedule III would remove that burden.
What rescheduling would not do, at least not directly, is solve the gray-market hemp product problem Griffith describes. That would require separate FDA rulemaking - and possibly congressional action - to establish a regulatory framework for cannabinoids in food, beverage, and consumer products. The FDA has been slow to move on that front. The gap between what rescheduling actually does and what the public and even some legislators assume it does is significant. Compliance professionals and multi-state operators watching this process should read the administrative hearing outcomes carefully rather than assuming immediate operational changes.
Why This Matters to Licensed Retailers and Brands
For dispensary operators, the political signal here is arguably as important as the regulatory mechanics. When a socially conservative Republican congressman from a rural Virginia district frames federal cannabis oversight as a public safety necessity - not a permissiveness issue - that reflects how the conversation has shifted. It's no longer only about adult-use legalization or state-level ballot measures. Regulatory legitimacy, product traceability, and consumer protection have become the vocabulary of the mainstream argument.
Licensed retailers have spent years and considerable capital building compliance infrastructure: METRC integrations, lab-tested inventory, age-verification protocols, trained staff. The market distortion created by unregulated hemp-derived products undercuts that investment. If federal rescheduling leads downstream to clearer FDA authority over cannabinoid products - and that's a real if - it could eventually tighten the standards applied to unlicensed retail channels and narrow the competitive gap that has frustrated compliant operators for years.
The June 29 hearing will focus on implementation mechanics, not the rescheduling decision itself. Operators, wholesalers, and compliance teams would do well to track those proceedings. The details will determine whether this regulatory shift reaches the retail floor in any meaningful way, or remains a headline that changes less than it appears to.
